Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Time between expanded disability status scale (EDSS) scores.

Zurawski J, Glanz BI, Chua A, Lokhande H, Rotstein D, Weiner H, Engler D, Chitnis T, Healy BC.

Mult Scler Relat Disord. 2019 Feb 5;30:98-103. doi: 10.1016/j.msard.2019.02.007. [Epub ahead of print]

PMID:
30763908
2.

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis.

Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC.

BMC Neurol. 2019 Feb 12;19(1):23. doi: 10.1186/s12883-019-1245-2.

3.

Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry.

Chi C, Shao X, Rhead B, Gonzales E, Smith JB, Xiang AH, Graves J, Waldman A, Lotze T, Schreiner T, Weinstock-Guttman B, Aaen G, Tillema JM, Ness J, Candee M, Krupp L, Gorman M, Benson L, Chitnis T, Mar S, Belman A, Casper TC, Rose J, Moodley M, Rensel M, Rodriguez M, Greenberg B, Kahn L, Rubin J, Schaefer C, Waubant E, Langer-Gould A, Barcellos LF.

PLoS Genet. 2019 Jan 17;15(1):e1007808. doi: 10.1371/journal.pgen.1007808. eCollection 2019 Jan.

4.

A young man in "double-trouble": Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings.

Bradshaw MJ, Lisak RP, Meltzer E, Melamed E, Lucas A, Freeman L, Frohman TC, Costello K, Balcer L, Galetta S, Chitnis T, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 19;6(1):e526. doi: 10.1212/NXI.0000000000000526. eCollection 2019 Jan. No abstract available.

5.

Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.

Desai RJ, Mahesri M, Gagne JJ, Hurley E, Tong A, Chitnis T, Minden S, Spettell CM, Matlin OS, Shrank WH, Choudhry NK.

J Manag Care Spec Pharm. 2019 Jan;25(1):113-121. doi: 10.18553/jmcp.2019.25.1.113.

6.

Several household chemical exposures are associated with pediatric-onset multiple sclerosis.

Mar S, Liang S, Waltz M, Casper TC, Goyal M, Greenberg B, Weinstock-Guttman B, Rodriguez M, Aaen G, Belman A, Barcellos LF, Rose J, Gorman M, Benson L, Candee M, Chitnis T, Harris Y, Kahn I, Roalsted S, Hart J, Lotze T, Moodley M, Ness J, Rensel M, Rubin J, Schreiner T, Tillema JM, Waldman A, Krupp L, Graves JS, Waubant E; U.S. Network of Pediatric Multiple Sclerosis Centers.

Ann Clin Transl Neurol. 2018 Oct 9;5(12):1513-1521. doi: 10.1002/acn3.663. eCollection 2018 Dec.

7.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

8.

Food allergies are associated with increased disease activity in multiple sclerosis.

Fakih R, Diaz-Cruz C, Chua AS, Gonzalez C, Healy BC, Sattarnezhad N, Glanz BI, Weiner HL, Chitnis T.

J Neurol Neurosurg Psychiatry. 2018 Dec 18. pii: jnnp-2018-319301. doi: 10.1136/jnnp-2018-319301. [Epub ahead of print]

PMID:
30563943
9.

Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis.

Aaen G, Waltz M, Vargas W, Makhani N, Ness J, Harris Y, Casper TC, Benson L, Candee M, Chitnis T, Gorman M, Graves J, Greenberg B, Lotze T, Mar S, Tillema JM, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Waldman A, Weinstock-Guttman B, Belman A, Waubant E, Krupp L.

J Child Neurol. 2018 Dec 17:883073818815041. doi: 10.1177/0883073818815041. [Epub ahead of print]

PMID:
30556452
10.

Beyond the band: A biomarker for pediatric MS?

Chitnis T.

Mult Scler. 2018 Nov;24(13):1655-1656. doi: 10.1177/1352458518803778. No abstract available.

PMID:
30422760
11.

Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.

Healy BC, Zurawski J, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI.

Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159. [Epub ahead of print]

PMID:
30381985
12.

Diet quality and risk of multiple sclerosis in two cohorts of US women.

Rotstein DL, Cortese M, Fung TT, Chitnis T, Ascherio A, Munger KL.

Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061. [Epub ahead of print]

PMID:
30351179
13.

Heterogeneity in association of remote herpesvirus infections and pediatric MS.

Nourbakhsh B, Rutatangwa A, Waltz M, Rensel M, Moodley M, Graves J, Casper TC, Waldman A, Belman A, Greenberg B, Goyal M, Harris Y, Kahn I, Lotze T, Mar S, Schreiner T, Aaen G, Hart J, Ness J, Rubin J, Tillema JM, Krupp L, Gorman M, Benson L, Rodriguez M, Chitnis T, Rose J, Candee M, Weinstock-Guttman B, Shao X, Barcellos L, James J, Waubant E; US Network of Pediatric MS Centers.

Ann Clin Transl Neurol. 2018 Sep 17;5(10):1222-1228. doi: 10.1002/acn3.636. eCollection 2018 Oct.

14.

Urban air quality and associations with pediatric multiple sclerosis.

Lavery AM, Waubant E, Casper TC, Roalstad S, Candee M, Rose J, Belman A, Weinstock-Guttman B, Aaen G, Tillema JM, Rodriguez M, Ness J, Harris Y, Graves J, Krupp L, Charvet L, Benson L, Gorman M, Moodley M, Rensel M, Goyal M, Mar S, Chitnis T, Schreiner T, Lotze T, Greenberg B, Kahn I, Rubin J, Waldman AT.

Ann Clin Transl Neurol. 2018 Sep 27;5(10):1146-1153. doi: 10.1002/acn3.616. eCollection 2018 Oct.

15.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
16.

Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.

Krysko KM, Graves J, Rensel M, Weinstock-Guttman B, Aaen G, Benson L, Chitnis T, Gorman M, Goyal M, Krupp L, Lotze T, Mar S, Rodriguez M, Rose J, Waltz M, Charles Casper T, Waubant E; US Network of Pediatric MS Centers.

Neurology. 2018 Nov 6;91(19):e1778-e1787. doi: 10.1212/WNL.0000000000006471. Epub 2018 Oct 17.

PMID:
30333163
17.

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.

Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chitnis T, Weiner HL.

J Neurol Sci. 2018 Nov 15;394:127-131. doi: 10.1016/j.jns.2018.09.020. Epub 2018 Sep 17.

PMID:
30248571
18.

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis.

Dastagir A, Healy BC, Chua AS, Chitnis T, Weiner HL, Bakshi R, Tauhid S.

eNeurologicalSci. 2018 Jul 4;12:42-46. doi: 10.1016/j.ensci.2018.07.002. eCollection 2018 Sep.

19.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
20.

Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.

Fakih R, Matiello M, Chitnis T, Stankiewicz JM.

J Neurol. 2018 Nov;265(11):2688-2694. doi: 10.1007/s00415-018-9050-1. Epub 2018 Sep 10.

PMID:
30203314
21.

Identification of MS-specific serum miRNAs in an international multicenter study.

Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. doi: 10.1212/NXI.0000000000000491. eCollection 2018 Sep.

22.

Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.

Khalid F, Healy BC, Dupuy SL, Chu R, Chitnis T, Bakshi R, Houtchens M.

J Neurol Sci. 2018 Sep 15;392:94-99. doi: 10.1016/j.jns.2018.06.025. Epub 2018 Jun 30.

PMID:
30031994
23.

Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis.

Leclaire K, Cecil A, LaRussa A, Stuart F, Hemond CC, Healy BC, Chitnis T, Weiner H, Huffman J, Glanz BI.

Int J MS Care. 2018 May-Jun;20(3):136-141. doi: 10.7224/1537-2073.2017-002.

24.

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.

Gärtner J, Chitnis T, Ghezzi A, Pohl D, Brück W, Häring DA, Karlsson G, Putzki N.

Mult Scler J Exp Transl Clin. 2018 May 25;4(2):2055217318778610. doi: 10.1177/2055217318778610. eCollection 2018 Apr-Jun.

25.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
26.

Pediatric Neuromyelitis Optica Spectrum Disorders.

Gombolay GY, Chitnis T.

Curr Treat Options Neurol. 2018 May 2;20(6):19. doi: 10.1007/s11940-018-0502-9. Review.

PMID:
29721683
27.

Complexity of MS management in the current treatment era.

Chitnis T, Giovannoni G, Trojano M.

Neurology. 2018 Apr 24;90(17):761-762. doi: 10.1212/WNL.0000000000005399. No abstract available.

PMID:
29686111
28.

Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis.

Suleiman L, Waubant E, Aaen G, Belman A, Benson L, Candee M, Chitnis T, Gorman M, Goyal M, Greenberg B, Harris Y, Hart J, Kahn I, Krupp L, Lotze T, Mar S, Moodley M, Ness J, Nourbakhsh B, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Tillema JM, Waldman A, Weinstock-Guttman B, Casper TC, Waltz M, Graves JS; Network of Pediatric Multiple Sclerosis Centers.

Mult Scler Relat Disord. 2018 May;22:103-107. doi: 10.1016/j.msard.2018.03.015. Epub 2018 Mar 26.

PMID:
29653437
29.

Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.

Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A, Diaz-Cruz C, Gholipour T, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Berry JD, Gandhi R.

Muscle Nerve. 2018 Aug;58(2):261-269. doi: 10.1002/mus.26106. Epub 2018 Mar 25.

PMID:
29466830
30.

Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.

Bove R, Healy BC, Musallam A, Soltany P, Diaz-Cruz C, Sattarnezhad N, Glanz BI, Kivisäkk P, Miller KK, Chitnis T.

Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768. [Epub ahead of print]

PMID:
29320952
31.

The role of testosterone in MS risk and course.

Chitnis T.

Mult Scler. 2018 Jan;24(1):36-41. doi: 10.1177/1352458517737395.

PMID:
29307293
32.

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.

Baharnoori M, Gonzalez CT, Chua A, Diaz-Cruz C, Healy BC, Stankiewicz J, Weiner HL, Chitnis T.

Mult Scler Relat Disord. 2018 Feb;20:51-57. doi: 10.1016/j.msard.2017.12.003. Epub 2017 Dec 14.

PMID:
29304497
33.

Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis.

Cavallari M, Egorova S, Healy BC, Palotai M, Prieto JC, Polgar-Turcsanyi M, Tauhid S, Anderson M, Glanz B, Chitnis T, Guttmann CRG.

J Neuroimaging. 2018 May;28(3):273-277. doi: 10.1111/jon.12490. Epub 2017 Dec 11.

PMID:
29226505
34.

Child Neurology: Primary angiitis of the CNS.

Kim G, Chitnis T.

Neurology. 2017 Dec 5;89(23):e268-e271. doi: 10.1212/WNL.0000000000004718. No abstract available.

PMID:
29203535
35.

Wearable biosensors to monitor disability in multiple sclerosis.

Bradshaw MJ, Farrow S, Motl RW, Chitnis T.

Neurol Clin Pract. 2017 Aug;7(4):354-362. doi: 10.1212/CPJ.0000000000000382. Review.

36.

A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.

Yousuf F, Dupuy SL, Tauhid S, Chu R, Kim G, Tummala S, Khalid F, Weiner HL, Chitnis T, Healy BC, Bakshi R.

J Neurol Sci. 2017 Dec 15;383:221-229. doi: 10.1016/j.jns.2017.10.019. Epub 2017 Oct 16.

37.

Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.

Eagle T, Stuart F, Chua AS, LaRussa A, Leclaire K, Cook SL, Chitnis T, Weiner HL, Glanz BI, Healy BC.

Mult Scler Relat Disord. 2017 Nov;18:196-201. doi: 10.1016/j.msard.2017.10.002. Epub 2017 Oct 5.

PMID:
29141809
38.

Examining the contributions of environmental quality to pediatric multiple sclerosis.

Lavery AM, Waldman AT, Charles Casper T, Roalstad S, Candee M, Rose J, Belman A, Weinstock-Guttman B, Aaen G, Tillema JM, Rodriguez M, Ness J, Harris Y, Graves J, Krupp L, Benson L, Gorman M, Moodley M, Rensel M, Goyal M, Mar S, Chitnis T, Schreiner T, Lotze T, Greenberg B, Kahn I, Rubin J, Waubant E; U.S. Network of Pediatric MS Centers.

Mult Scler Relat Disord. 2017 Nov;18:164-169. doi: 10.1016/j.msard.2017.09.004. Epub 2017 Sep 7.

39.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B.

Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1.

40.

The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis.

Diaz-Cruz C, Chua AS, Malik MT, Kaplan T, Glanz BI, Egorova S, Guttmann CRG, Bakshi R, Weiner HL, Healy BC, Chitnis T.

Mult Scler Relat Disord. 2017 Oct;17:47-53. doi: 10.1016/j.msard.2017.06.011. Epub 2017 Jun 27.

PMID:
29055473
41.

Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.

Azary S, Schreiner T, Graves J, Waldman A, Belman A, Guttman BW, Aaen G, Tillema JM, Mar S, Hart J, Ness J, Harris Y, Krupp L, Gorman M, Benson L, Rodriguez M, Chitnis T, Rose J, Barcellos LF, Lotze T, Carmichael SL, Roalstad S, Casper CT, Waubant E.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):28-33. doi: 10.1136/jnnp-2017-315936. Epub 2017 Oct 9.

42.

Genetic risk factors for pediatric-onset multiple sclerosis.

Gianfrancesco MA, Stridh P, Shao X, Rhead B, Graves JS, Chitnis T, Waldman A, Lotze T, Schreiner T, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema JM, Hart J, Caillier S, Ness J, Harris Y, Rubin J, Candee M, Krupp L, Gorman M, Benson L, Rodriguez M, Mar S, Kahn I, Rose J, Roalstad S, Casper TC, Shen L, Quach H, Quach D, Hillert J, Hedstrom A, Olsson T, Kockum I, Alfredsson L, Schaefer C, Barcellos LF, Waubant E; Network of Pediatric Multiple Sclerosis Centers.

Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551. [Epub ahead of print]

PMID:
28980494
43.

Exposure to particulate matter air pollution and risk of multiple sclerosis in two large cohorts of US nurses.

Palacios N, Munger KL, Fitzgerald KC, Hart JE, Chitnis T, Ascherio A, Laden F.

Environ Int. 2017 Dec;109:64-72. doi: 10.1016/j.envint.2017.07.013. Epub 2017 Sep 20.

PMID:
28938101
44.

CNS inflammation and neurodegeneration.

Chitnis T, Weiner HL.

J Clin Invest. 2017 Oct 2;127(10):3577-3587. doi: 10.1172/JCI90609. Epub 2017 Sep 5.

45.

Depression and fatigue in patients with multiple sclerosis.

Greeke EE, Chua AS, Healy BC, Rintell DJ, Chitnis T, Glanz BI.

J Neurol Sci. 2017 Sep 15;380:236-241. doi: 10.1016/j.jns.2017.07.047. Epub 2017 Jul 31.

PMID:
28870578
46.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2018 Oct;24(11):1485-1498. doi: 10.1177/1352458517726657. Epub 2017 Aug 29.

PMID:
28847219
47.

No association between dietary sodium intake and the risk of multiple sclerosis.

Cortese M, Yuan C, Chitnis T, Ascherio A, Munger KL.

Neurology. 2017 Sep 26;89(13):1322-1329. doi: 10.1212/WNL.0000000000004417. Epub 2017 Aug 25.

48.

Dietary factors and pediatric multiple sclerosis: A case-control study.

Pakpoor J, Seminatore B, Graves JS, Schreiner T, Waldman AT, Lotze TE, Belman A, Greenberg BM, Weinstock-Guttman B, Aaen G, Tillema JM, McDonald JC, Hart J, Ness JM, Harris Y, Rubin J, Candee M, Krupp L, Gorman M, Benson L, Rodriguez M, Chitnis T, Mar S, Kahn I, Rose J, Carmichael SL, Roalstad S, Waltz M, Casper TC, Waubant E; US Network of Pediatric Multiple Sclerosis Centers.

Mult Scler. 2018 Jul;24(8):1067-1076. doi: 10.1177/1352458517713343. Epub 2017 Jun 13.

PMID:
28608728
49.

Experience with long-term rituximab use in a multiple sclerosis clinic.

Barra ME, Soni D, Vo KH, Chitnis T, Stankiewicz JM.

Mult Scler J Exp Transl Clin. 2016 Oct 9;2:2055217316672100. doi: 10.1177/2055217316672100. eCollection 2016 Jan-Dec.

50.

Risk attitudes and risk perceptions in individuals with multiple sclerosis.

Glanz BI, Greeke E, LaRussa A, Stuart F, Rintell DJ, Chitnis T, Healy BC.

Mult Scler J Exp Transl Clin. 2016 Sep 2;2:2055217316665406. doi: 10.1177/2055217316665406. eCollection 2016 Jan-Dec.

Supplemental Content

Loading ...
Support Center